Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET/CT imaging: the PSMA PET progression criteria
In around 20% of men with prostate cancer, metastasis develops during the course of their
disease. Accordingly, discovering and developing new potent treatment strategies for …
disease. Accordingly, discovering and developing new potent treatment strategies for …
[HTML][HTML] Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
Purpose Prostate-specific membrane antigen (PSMA) positron emission tomography
(PET)/computed tomography (CT) is used for (re) staging prostate cancer (PCa) and as a …
(PET)/computed tomography (CT) is used for (re) staging prostate cancer (PCa) and as a …
68Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy
QA Shagera, C Artigas, I Karfis, G Critchi… - Journal of Nuclear …, 2022 - Soc Nuclear Med
We aimed to evaluate the role of PET targeting the prostate-specific membrane antigen
(PSMA) for response assessment in metastatic prostate cancer (PCa) patients treated with …
(PSMA) for response assessment in metastatic prostate cancer (PCa) patients treated with …
Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international …
Our objective was to develop version 1.0 of a novel framework for response evaluation
criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) and a composite …
criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) and a composite …
Response assessment using [68Ga]Ga‐PSMA ligand PET in patients undergoing systemic therapy for metastatic castration‐resistant prostate cancer
Background To assess which parameters of [68Ga] Ga‐PSMA‐11 positron emission
tomography (PSMA‐PET) predict response to systemic therapies in metastatic (m) castration …
tomography (PSMA‐PET) predict response to systemic therapies in metastatic (m) castration …
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 …
Abstract Purpose To compare the Response Evaluation Criteria in Solid Tumors (RECIST)
1.1, the adapted Prostate Cancer Working Group Criteria 3 (aPCWG3), the adapted Positron …
1.1, the adapted Prostate Cancer Working Group Criteria 3 (aPCWG3), the adapted Positron …
[HTML][HTML] Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
C Mingels, KP Bohn, A Rominger… - European journal of …, 2022 - Springer
Aim Despite increasing use for the detection of biochemically recurrent prostate cancer
(rPC), the diagnostic accuracy of positron emission tomography/computed tomography …
(rPC), the diagnostic accuracy of positron emission tomography/computed tomography …
Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
AK Seitz, I Rauscher, B Haller, M Krönke… - European journal of …, 2018 - Springer
Purpose To investigate the value of 68 Ga-HBED-CC PSMA (68 Ga-PSMA) PET/CT for
response assessment in metastatic castration-sensitive and castration-resistant prostate …
response assessment in metastatic castration-sensitive and castration-resistant prostate …
[HTML][HTML] Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)
Context Prostate-specific membrane antigen (PSMA) targeting positron emission
tomography (PET) is emerging to become a reference imaging tool for the staging and …
tomography (PET) is emerging to become a reference imaging tool for the staging and …
Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent …
Context Prostate-specific membrane antigen (PSMA) is a promising molecular target for
prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to …
prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to …
Related searches
- systemic therapy response assessment
- psma pet prostate cancer
- psma pet measuring response
- psma pet recip 1.0
- psma pet primary diagnosis
- prostate cancer response assessment
- ligand pet response assessment
- cc psma response assessment
- systemic therapy prostate cancer
- systemic therapy ligand pet
- systemic therapy ga psma
- ga hbed response assessment
- docetaxel chemotherapy response assessment
- outcome prediction response assessment
- prostate cancer biochemical recurrence
- prostate cancer ga hbed